United Therapeutics Corporation Stock Price and Value Analysis

United Therapeutics Corporation (NasdaqGS:UTHR) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold United Therapeutics Corporation to reach your target.

Target type

UTHR Free Cash Flow Trend

Free Cash Flow trendline for UTHR
Free Cash Flow trendline for United Therapeutics Corporation
CSV

Based on historical returns, we believe that United Therapeutics Corporation can grow its free cash at a rate of about 13%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a great rate!
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the UTHR Numbers

UTHR Price
(United Therapeutics Corporation stock price per share)
$554.73
[?] UTHR Fair Price
(based on intrinsic value)
$428.24
[?] UTHR Safety Price (based on a variable margin of safety) $256.94
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 3% higher than other Healthcare stocks
[?] PE Ratio versus Industry 58% lower than other Drug Manufacturers - General stocks
[?] Cash Yield 1.55%
[?] Free Cash Flow Jitter 57%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,837,654 shares shorted. With 38,939,724 shares available for purchase and an average trading volume over the past 10 trading days of 436,750, it would take at least 4.2 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 1082554 -165
2009 1082554 -10.2
2010 1082554 132
2011 1082554 182
2012 1082554 246
2013 1082554 367
2014 1082554 306
2015 1082554 327
2016 1082554 588
2017 1082554 424
2018 1082554 697
2019 1082554 -295
2020 1082554 665
2021 1082554 491
2022 1082554 685
2023 1082554 851
2024 1082554 1,168
2025 1082554 1,310

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 5 fiscal years from 2021 to 2025 with positive net income, operating cash flow totaled $5,267 million against net income of $4,718 million, or 1.12 times.

In 2025, operating cash flow was 1.17 times net income, compared with 1.09 times for the earliest three years (2021 to 2023).

In 2025, capital expenditures were $521 million, 33.3% of operating cash flow of $1,561 million, which leaves an estimated $1,041 million after capex. Across the 5 years with reported capex, it averaged 23.9% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2021 476 598 121 1.26
2022 727 803 139 1.10
2023 985 978 230 0.99
2024 1,195 1,327 247 1.11
2025 1,335 1,561 521 1.17

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 9 fiscal years from 2011 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $4,917 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 9 of the 9 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $4,070 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $1,000 million, 76.3% of estimated free cash flow of $1,310 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2011 182 n/a 212 212 116.7%
2012 246 n/a 188 188 76.3%
2013 367 n/a 42.4 42.4 11.6%
2014 306 n/a 483 483 157.8%
2015 327 n/a 395 395 120.5%
2016 588 n/a 500 500 85.1%
2017 424 n/a 250 250 59.0%
2024 1,168 n/a 1,000 1,000 85.6%
2025 1,310 n/a 1,000 1,000 76.3%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $281 million in 2008 and $3,183 million in 2025, a compound annual growth rate of 15.3% over 17 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 10.6% from 2024 to 2025.

Our estimated free cash flow was $1,310 million in 2025, 41.2% of revenue. In 2008 the estimated margin was negative 58.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2008 281 -165 -58.6%
2009 359 -10.2 -2.8%
2010 593 132 22.3%
2011 743 182 24.4%
2012 916 246 26.9%
2013 1,117 367 32.8%
2014 1,289 306 23.8%
2015 1,466 327 22.3%
2016 1,599 588 36.8%
2017 1,725 424 24.5%
2018 1,628 697 42.8%
2019 1,449 -295 -20.4%
2020 1,483 665 44.9%
2021 1,686 491 29.1%
2022 1,936 685 35.4%
2023 2,328 851 36.6%
2024 2,877 1,168 40.6%
2025 3,183 1,310 41.2%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $1,557 million against total liabilities of $784 million, or 198.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 9.9% of total assets in 2025, compared with 37.9% in 2009, a decrease of 28.0 percentage points.

Stockholders equity was $7,096 million in 2025, compared with $653 million in 2009, a rise of 986.7%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 22.7% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 1,052 100 399 653
2010 1,432 252 548 884
2011 1,518 168 570 948
2012 1,627 159 543 1,084
2013 2,088 284 828 1,259
2014 1,884 398 642 1,243
2015 2,184 832 596 1,589
2016 2,326 1,023 474 1,851
2017 2,879 705 778 2,102
2018 3,401 669 612 2,789
2019 3,913 738 1,133 2,780
2020 4,615 739 1,220 3,395
2021 5,169 895 1,210 3,959
2022 6,045 961 1,248 4,797
2023 7,167 1,208 1,182 5,985
2024 7,364 1,697 920 6,444
2025 7,880 1,557 784 7,096

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $554.73, our model's value equals that price if free cash flow grows an average of 18.9 percent a year over the 10 projection years. Our model assumes 13.5 percent a year for this stock, so the price implies growth of 18.9 percent, which is above the 13.5 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $366 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $443.78 14.3%
Current price $554.73 18.9%
20 percent above the current price $665.68 22.3%
Our model (stored fair price) $428.24 13.5%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Of the 18 fiscal years we can see for United Therapeutics Corporation under its current filer, 15 show positive free cash flow.

Our fair value estimate for United Therapeutics Corporation is $428.24, below its current price of $554.73.

Year-to-year variability in free cash flow is volatile, measured at 57%.

We do not have a dividend yield for United Therapeutics Corporation.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 3% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 58% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to United Therapeutics Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
United Therapeutics Corporation (UTHR) 23,625 20.9 - 1.5% 30% above
Viatris (VTRS) 22,505 - 2.4% - 2% below
Zoetis (ZTS) 32,144 13.5 2.6% - 865% above
Jazz Pharmaceuticals plc (JAZZ) 14,780 68.1 - 3.4% 53% below
Elanco Animal Health Incorporated (ELAN) 12,866 - - - 96% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Corcept Therapeutics Incorporated (CORT) 7,112 48.9 - 0.0% 858% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1082554.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 3 of the 18 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: UTHR annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in UTHR

Does United Therapeutics Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: UTHR

This example shows how we apply the Trendshare checklist to UTHR: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 554.73
    • Market cap: $24B
    • EPS: 26.49
  2. Step 2 — Valuation checks

    • P/E: 20.941
    • FCF yield: 1.5%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.